


## GSK-F1

<b>Cat. No.:</b>	HY-100603
<b>CAS No.:</b>	1402345-92-9
<b>Molecular Formula:</b>	C <sub>27</sub> H <sub>18</sub> F <sub>5</sub> N <sub>5</sub> O <sub>4</sub> S
<b>Molecular Weight:</b>	603.52
<b>Target:</b>	PI4K; PI3K
<b>Pathway:</b>	PI3K/Akt/mTOR
<b>Storage:</b>	-20°C, sealed storage, away from moisture and light * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)



## SOLVENT & SOLUBILITY

### In Vitro

DMSO : 125 mg/mL (207.12 mM; Need ultrasonic)

Concentration	Mass		
	1 mg	5 mg	10 mg
1 mM	1.6569 mL	8.2847 mL	16.5695 mL
5 mM	0.3314 mL	1.6569 mL	3.3139 mL
10 mM	0.1657 mL	0.8285 mL	1.6569 mL

Please refer to the solubility information to select the appropriate solvent.

## BIOLOGICAL ACTIVITY

### Description

GSK-F1 (Compound F1) is an orally active PI4KA inhibitor with pIC<sub>50</sub> values of 8.0, 5.9, 5.8, 5.9, 5.9 and 6.4 against PI4KA, PI4KB, PI3KA, PI3KB, PI3KG and PI3KD, respectively. GSK-F1 can be used for HCV infection research<sup>[1]</sup>.

### IC<sub>50</sub> & Target

PI4KA 8.0 (pIC <sub>50</sub> )	PI3KD 6.4 (pIC <sub>50</sub> )	PI4KB 5.9 (pIC <sub>50</sub> )	PI3KB 5.9 (pIC <sub>50</sub> )
PI3KG 5.9 (pIC <sub>50</sub> )	PI3KA 5.8 (pIC <sub>50</sub> )		

## REFERENCES

[1]. Bojjireddy N, et al. Pharmacological and genetic targeting of the PI4KA enzyme reveals its important role in maintaining plasma membrane phosphatidylinositol 4-phosphate and phosphatidylinositol 4,5-bisphosphate levels. J Biol Chem. 2014 Feb 28;289(9):6120-32.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA